Novavax, Inc. short interest in 2026
In 2026, Novavax, Inc.'s disclosed short interest ran from 32.79% of shares outstanding on 15 Jan 2026 to 30.24% on 15 Sep 2026, a change of -2.55 percentage points. The year's high was 32.79% on 15 Jan 2026 and its low 26.65% on 15 Jul 2026, averaging 29.21% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 17.25 days on 30 Apr 2026. Full history: Novavax, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 32.79% (15 Jan 2026)
- End of year
- 30.24% (15 Sep 2026)
- Change
- -2.55 pp
- High
- 32.79% (15 Jan 2026)
- Low
- 26.65% (15 Jul 2026)
- Average
- 29.21%
- Highest days to cover
- 17.25 (30 Apr 2026)
- SEC filings marked
- 7
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 32.79% | 10.84 | results (8-K) |
| 30 Jan 2026 | 31.50% | 6.55 | |
| 13 Feb 2026 | 31.29% | 13.51 | |
| 27 Feb 2026 | 31.25% | 8.75 | 10-K filed, results (8-K) |
| 13 Mar 2026 | 29.84% | 11.29 | |
| 31 Mar 2026 | 27.61% | 10.62 | |
| 15 Apr 2026 | 28.44% | 15.00 | |
| 30 Apr 2026 | 30.09% | 17.25 | |
| 15 May 2026 | 27.54% | 6.35 | 10-Q filed, results (8-K) |
| 29 May 2026 | 27.95% | 7.84 | |
| 15 Jun 2026 | 27.43% | 10.79 | |
| 30 Jun 2026 | 27.86% | 9.28 | |
| 15 Jul 2026 | 26.65% | 11.43 | |
| 31 Jul 2026 | 27.68% | 16.63 | |
| 14 Aug 2026 | 28.79% | 14.03 | 10-Q filed, results (8-K) |
| 31 Aug 2026 | 29.58% | 8.61 | |
| 15 Sep 2026 | 30.24% | 9.28 |
See also: Novavax, Inc.'s full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.